ClinicalTrials.gg
CompletedNCT01477632Updated Jan 15, 2016

Bioavailability of Three Oral Formulations for Hormone Replacement Therapy in Postmenopausal Women

A Phase 1 interventional study of 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) and 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) in Menopause and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-15.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
Female
01

Study summary

This trial is conducted in Europe. The aim of this trial is to determine the extent of bioavailability of two low dose estradiol/norethisterone acetate (NETA) preparations with a marketed estradiol/norethisterone acetate (NETA) preparation.

02

Conditions studied

  • Menopause
  • Healthy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy
  • Caucasian race
  • Smoking (up to 5 cig./per day) is allowed
  • Good state of health: evidenced by medical history, physical examination including gynecological examination, results of laboratory examination

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to trial products or related products
  • Previous participation in this trial
  • Previous estrogen and/or progestin hormone replacement therapy
  • Known, suspected or history of breast cancer
  • Systolic blood pressure (BP) at least 160 mm Hg and/or diastolic BP at least 100 mm Hg, currently treated or untreated
  • (BMI) above 35.0 kg/m\^2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    A

    Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

  • Experimental
    B

    Drug: 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)

  • Active comparator
    C

    Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

Interventions

  • Drug0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    A single oral dose of 2 tablets under fasting conditions

  • Drug0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    A single oral dose of 2 tablets under fasting conditions

  • Drug1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    A single oral dose of 1 tablet under fasting conditions

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC(0-∞))

  2. Maximal concentration (Cmax)

  3. Time to maximum (tmax)

Secondary outcomes

  1. Area Under the Curve (AUC) from dosing up to last sample

  2. Terminal half-life (t½)

07

Study locations

1 site
  • Neu-Ulm, 89231, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2011
First posted
Nov 22, 2011
Start
Mar 2005
Primary completionActual
Jun 2005
CompletionActual
Jun 2005
Last update
Jan 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01477632
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Mar 2005
Primary completion
Jun 2005
Completion
Jun 2005
Last update
Jan 15, 2016

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Norethindrone Acetate

Start the discussion